Irene López

This paper analyzes 100,526 GWAS to identify pleiotropic genes and their therapeutic implications, finding that highly pleiotropic genes are associated with safety liabilities and that combining PAV support with intermediate pleiotropy improves therapeutic success.

This study systematically analyzes chemical probe literature to identify target-disease associations, revealing their utility in early therapeutic discovery and highlighting opportunities for repurposing.

The paper analyzes reasons for clinical trial failures using NLP and shows that genetic evidence improves trial success chances.